Date: 2015-12-05
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando
Company: ADC Therapeutics (Switzerland)
Product: ADCT-301
Action mechanism: antibody drug conjugate. ADCT-301 combines HuMax®-TAC, a human monoclonal antibody targeting CD25 (the alpha chain of the IL-2 receptor) created by Genmab A/S, with a dimeric pyrrolobenzodiazepine (PBD) warhead. The data confirm the mechanism of action of ADCT-301 and provide relevant pharmacodynamic assays for use in clinical development.
Disease: hematological cancers including lymphoma and leukemia
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest news: * On December 5, 2015, ADC Therapeutics, an oncology drug development company, presented pre-clinical results for ADCT-301, its novel Antibody Drug Conjugate (ADC) in hematological tumours at the 57th American Society of Hematology (ASH) Annual Meeting, December 5-8, in Orlando, Florida. ADCT-301 is currently in Phase I for lymphoma and leukemia. The pre-clinical studies referenced above were conducted jointly by ADC Therapeutics, Spirogen (a division of AstraZeneca) and University College London, London.
